Priligy 60 mg tabletti, kalvopäällysteinen Фінляндія - фінська - Fimea (Suomen lääkevirasto)

priligy 60 mg tabletti, kalvopäällysteinen

berlin-chemie ag - dapoxetine hydrochloride - tabletti, kalvopäällysteinen - 60 mg - dapoksetiini

MIDAZOLAM ORPHA 15 mg tabletti, kalvopäällysteinen Фінляндія - фінська - Fimea (Suomen lääkevirasto)

midazolam orpha 15 mg tabletti, kalvopäällysteinen

orpha-devel handels und vertriebs gmbh - midazolami maleas - tabletti, kalvopäällysteinen - 15 mg - midatsolaami

Pyrukynd Європейський Союз - фінська - EMA (European Medicines Agency)

pyrukynd

agios netherlands b.v. - mitapivat sulfate - genetic diseases, inborn; anemia, hemolytic - other hematological agents - pyrukynd is indicated for the treatment of pyruvate kinase deficiency (pk deficiency) in adult patients (see section 4.

Tibsovo Європейський Союз - фінська - EMA (European Medicines Agency)

tibsovo

les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - antineoplastiset aineet - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.

Orserdu Європейський Союз - фінська - EMA (European Medicines Agency)

orserdu

stemline therapeutics b.v. - elacestrant - rintojen kasvaimet - endokriinihoito - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.

Spevigo Європейський Союз - фінська - EMA (European Medicines Agency)

spevigo

boehringer ingelheim international gmbh - spesolimab - psoriasis - immunosuppressantit - spevigo is indicated for the treatment of flares in adult patients with generalised pustular psoriasis (gpp) as monotherapy.

HALCION 0.125 mg tabletti Фінляндія - фінська - Fimea (Suomen lääkevirasto)

halcion 0.125 mg tabletti

pfizer oy pfizer oy - triazolamum - tabletti - 0.125 mg - triatsolaami

CLARITHROMYCIN RATIOPHARM 250 mg tabletti, kalvopäällysteinen Фінляндія - фінська - Fimea (Suomen lääkevirasto)

clarithromycin ratiopharm 250 mg tabletti, kalvopäällysteinen

teva sweden ab - clarithromycinum - tabletti, kalvopäällysteinen - 250 mg - klaritromysiini

CLARITHROMYCIN RATIOPHARM 500 mg tabletti, kalvopäällysteinen Фінляндія - фінська - Fimea (Suomen lääkevirasto)

clarithromycin ratiopharm 500 mg tabletti, kalvopäällysteinen

teva sweden ab - clarithromycinum - tabletti, kalvopäällysteinen - 500 mg - klaritromysiini

Torisel Європейський Союз - фінська - EMA (European Medicines Agency)

torisel

pfizer europe ma eeig - temsirolimuusin - carcinoma, renal cell; lymphoma, mantle-cell - antineoplastiset aineet - munuaisten-cell carcinomatorisel on tarkoitettu käytettäväksi ensilinjan hoitoon aikuispotilaille, joilla on pitkälle edennyt munuaisten-cell carcinoma (rcc), joka on vähintään kolme-kuusi ennustavia riskitekijöitä. mantle-cell lymphomatorisel on tarkoitettu aikuisille potilaille, joilla on uusiutunut ja / tai vaikeahoitoinen vaipan-solun lymfooman (mcl).